In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1836 News Items found
Roundup
ASH meeting signage
Advances in Myeloma, Lymphoma, and Bone Marrow Transplant Announced at the 2018 ASH Meeting

Learn more about the work of MSK researchers being presented at the 2018 meeting of the American Society of Hematology.
Memorial Sloan Kettering Breast Cancer Experts to Gather at Annual San Antonio Breast Cancer Symposium

Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.
Finding
Jonathan Peled speaks during a press conference
Gut Microbes May Protect People Having Bone Marrow Transplants

For the first time, researchers have found an association between the makeup of the microorganisms in the body before a bone marrow transplant and a patient’s survival afterward.
Q&A
Ethics Committee Chair Louis Voigt
8 Questions with Louis Voigt, an Expert on Medical Ethics

Learn about Louis Voigt, a critical care medicine specialist who is Chair of MSK's Ethics Committee.
In the Clinic
scientific image
Personalized Medicine 2.0: MSK Leads the Way in the Study of Drug Resistance in Lung Cancer

Overcoming resistance to drug treatment for lung cancer is a critical challenge.
In the Clinic
A tube of blood superimposed on a lung and a DNA helix
Liquid Biopsy Is Effective at Guiding Treatment of Lung Cancer, Study Finds

The initial results of an ongoing study show that a liquid biopsy has advantages over a tissue biopsy for people with lung cancer.
Feature
MSK medical oncologist Alexander Drilon
First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
Milestone Precision Medicine Decision: FDA Approves the First Treatment with an Initial Tumor-Agnostic Indication

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.
In the Lab
An illustration shows Helios, the ancient Greek sun god, unwinding DNA
Something New Under the Sun: Study in Leukemia Finds Role for Helios Protein

MSK researchers have found that a protein that contributes to one type of leukemia when it’s missing can lead to the formation of a different leukemia type when it’s present.
In the News
Male scientist speaking in front of a screen
Symposium Celebrates 15 Years of Developmental Biology at the Sloan Kettering Institute

Scientists came to give talks and celebrate the achievements that the program has made under the leadership of Kathryn Anderson.